The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Open accessAbstract
Pharmacokinetic properties of oligonucleotides are largely driven by chemistry of the backbone and thus are sequence independent within a chemical class. Tissue bioavailability (% of administered dose) is assisted by plasma protein binding that limits glomerular filtration and ultimate urinary excretion of oligonucleotides. The substitution of one non-bridging oxygen with the more hydrophobic sulfur atom (phosphorothioate) increases both plasma stability and plasma protein binding and thus, ultimately, tissue bioavailability. Additional modifications of the sugar at the 2' position, increase RNA binding affinity and significantly increase potency, tissue half-life and prolong RNA inhibitory activity. Oligonucleotides modified in this manner consistently exhibit the highest tissue bioavailability (>90%). Systemic biodistribution is broad, and organs typically with highest concentrations are liver and kidney followed by bone marrow, adipocytes, and lymph nodes. Cell uptake is predominantly mediated by endocytosis. Both size and charge for most oligonucleotides prevents distribution across the blood brain barrier. However, modified single-strand oligonucleotides administered by intrathecal injection into the CSF distribute broadly in the CNS. The majority of intracellular oligonucleotide distribution following systemic or local administration occurs rapidly in just a few hours following administration and is facilitated by rapid endocytotic uptake mechanisms. Further understanding of the intracellular trafficking of oligonucleotides may provide further enhancements in design and ultimate potency of antisense oligonucleotides in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Self-citationEteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationPrakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
Self-citationKinetic analysis of the RNAi enzyme complex
Haley, B., & Zamore, P. D. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb780 · Cited by 544
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., & Thornton, C. A. (2012) · Nature · doi:10.1038/nature11362 · Cited by 502
Self-citationZinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142298199 · Cited by 414
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Self-citationRigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Self-citationKoller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281
Self-citationAntisense Drug Technology: Principles: Strategies, and Applications
(2021) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 268
Zhang, H., Cook, J., Nickel, J., Yu, R., Stecker, K., Myers, K., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268
Self-citationYu, R. Z., Kim, T.-W., Hong, A., Watanabe, T. A., Gaus, H. J., & Geary, R. S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012401 · Cited by 244
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications
Szymkowski, D. E. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02123-7 · Cited by 218
Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice
Butler, M., McKay, R. A., Popoff, I. J., Gaarde, W. A., Witchell, D., Murray, S. F., Dean, N. M., Bhanot, S., & Monia, B. P. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1028 · Cited by 216
Crooke, S. T., & Geary, R. S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04469.x · Cited by 171
Self-citationLieberman, A. P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X. X., Cortes, C. J., Bennett, C. F., Monia, B. P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.008 · Cited by 169
Self-citationAltmann, K.-H., Dean, N. M., Fabbro, D., Freier, S. M., Geiger, T., Häner, R., Hüsken, D., Martin, P., Monia, B. P., Müller, M., et al. (1996) · CHIMIA · doi:10.2533/chimia.1996.168 · Cited by 169
Cortes, C. J., Ling, S.-C., Guo, L. T., Hung, G., Tsunemi, T., Ly, L., Tokunaga, S., Lopez, E., Sopher, B. L., Bennett, C. F., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.001 · Cited by 166
Self-citationØstergaard, M. E., Southwell, A. L., Kordasiewicz, H., Watt, A. T., Skotte, N. H., Doty, C. N., Vaid, K., Villanueva, E. B., Swayze, E. E., Frank Bennett, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt725 · Cited by 163
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
AMANTANA, A., & IVERSEN, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.07.001 · Cited by 163
Rondinone, C. M., Trevillyan, J. M., Clampit, J., Gum, R. J., Berg, C., Kroeger, P., Frost, L., Zinker, B. A., Reilly, R., Ulrich, R., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2405 · Cited by 159
Clinical pharmacokinetics of second generation antisense oligonucleotides
Yu, R. Z., Grundy, J. S., & Geary, R. S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.737320 · Cited by 136
Self-citationHung, G., Xiao, X., Peralta, R. Q., Bhattacharjee, G., Murray, S., Norris, D., Guo, S., & Monia, B. P. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0443 · Cited by 131
Self-citationYu, R. Z., Lemonidis, K. M., Graham, M. J., Matson, J. E., Crooke, R. M., Tribble, D. L., Wedel, M. K., Levin, A. A., & Geary, R. S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.005 · Cited by 125
Self-citationChi, K. N., Siu, L. L., Hirte, H., Hotte, S. J., Knox, J., Kollmansberger, C. K., Gleave, M. E., Guns, E. S. T., Powers, J., Walsh, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1310 · Cited by 119
Pharmacokinetics and Tissue Distribution of a Peptide Nucleic Acid After Intravenous Administration
McMahon, B. M., Mays, D. C., Lipsky, J. J., Stewart, J. A., Fauq, A. H., & Richelson, E. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760070803 · Cited by 106
Talbot, D. C., Ranson, M., Davies, J., Lahn, M., Callies, S., André, V., KADAM, S. K., Burgess, M., Slapak, C. A., Olsen, A. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1932 · Cited by 100
Liang, X., Shen, W., Sun, H., Prakash, T. P., & Crooke, S. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku484 · Cited by 94
Geary, R. S., Wancewicz, E. V., Matson, J. E., Pearce, M. E., Siwkowski, A. M., Swayze, E. E., & Bennett, F. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.013 · Cited by 87
Self-citationThompson, J. D., Kornbrust, D. J., Foy, J. W.-D., Solano, E. C. R., Schneider, D. J., Feinstein, E., Molitoris, B. A., & Erlich, S. S. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0371 · Cited by 85
Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs
Yu, R., Geary, R., & Levin, A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-14 · Cited by 59
Self-citationMechanisms of Antisense Drug Action, an Introduction
Vickers, T., Wu, H., Crooke, S., & Lima, W. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-7 · Cited by 49
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat
Waring, J. F., Ciurlionis, R., Clampit, J. E., Morgan, S. J., Gum, R. J., Jolly, R. A., Kroeger, P., Frost, L., Trevillyan, J. M., Zinker, B. A., et al. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(03)00008-x · Cited by 47
Geary, R. S., Yu, R. Z., Siwkowski, A., et al. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-19 · Cited by 32
Self-citationAntisense therapies for cancer
MacLeod, A. R. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.04.002 · Cited by 6
Cited by
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationPatient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Metadata
- Authors
- Geary, R. S., Norris, D., Yu, R., & Bennett, C. F.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 87
- Pages
- 46-51
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2033425827
- Cited by
- 845
- References
- 42
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.